Clinical Trial Update: Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Luveltamab Tazevibulin in adults with advanced or metastatic non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Luveltamab Tazevibulin

Snippet

Sponsor: Sutro Biopharma, Inc. | Conditions: Lung Cancer, Lung Cancer Metastatic | Phase 2 | Status: WITHDRAWN